Bestillerforum reviewed nine methods and updated two cases

NHTA — Mon, 16 Mar 2026 15:10:43 +0000

Norway’s Bestillerforum for new methods has completed its meeting on 16 March 2026, and a preliminary protocol has been published.

Methods discussed (nine total):

Medicines (seven): mepolizumab (Nucala) for uncontrolled COPD with elevated eosinophils; mirdametinib (Ezmekly) for inoperable plexiform neurofibromas in NF1 (paediatric and adult requests); nirogacestat (Ogsiveo) for progressive desmoid tumours; rilzabrutinib (Wayrilz) for refractory ITP; nivolumab (Opdivo) + AVD for previously untreated stage III–IV classical Hodgkin lymphoma (≥12 years); lanadelumab (Takhzyro) extension to ages 2–11 for hereditary angioedema prophylaxis; tiratrikol (Emcitate) for peripheral thyrotoxicosis in MCT8 deficiency.
Medical devices/diagnostics (two): DynamX coronary stent for PCI; Airsonett Air 4 (temperature-controlled laminar airflow) for severe allergic asthma.

Updated assignment: apremilast for oral ulcers associated with Behçet’s disease (ID2019_099).

Cancelled assignments: acalabrutinib (Calquence) + bendamustine + rituximab for untreated mantle cell lymphoma (ID2024_082); AI-based analysis of epileptic seizures (Nelli®) (ID2025_019).

Indlægget Bestillerforum reviewed nine methods and updated two cases blev først udgivet på NHTA.

Norway agrees Hemgenix after new negotiated price

NHTA — Mon, 16 Mar 2026 14:59:57 +0000

At its March meeting, Norwegian decision forum (Beslutningsforum) handled 18 cases and approved introduction in 13.

Key decisions (selected):

Etranacogene dezaparvovec (Hemgenix) was introduced for adults with moderate to severe haemophilia B. The forum noted it is a one-time treatment with the aim of replacing regular factor IX substitution therapy, meaning patients may avoid frequent infusions.
The forum’s chair, Jan Frich, said Hemgenix was not introduced when discussed in November due to uncertainty about how long the effect lasts and a high price; a newly negotiated price enabled approval.
Three non-small cell lung cancer medicines were introduced: tislelizumab (Tevimbra), osimertinib (Tagrisso) and tepotinib (Tepmetko).
Ciltacabtagene autoleucel (Carvykti) was not introduced for relapsed/refractory multiple myeloma; the forum cited lack of cost-effectiveness at the offered price and significant budget impact, and asked Sykehusinnkjøp to resume negotiations.

Indlægget Norway agrees Hemgenix after new negotiated price blev først udgivet på NHTA.

nye metoder Arkiv - NHTA

Bestillerforum reviewed nine methods and updated two cases

Norway agrees Hemgenix after new negotiated price